What is new in heart failure guidelines ESC 2012 – eplerenone Review article
Article Sidebar
Published:
Dec 31, 2012
Keywords:
guidelines, heart failure, eplerenone
Main Article Content
Abstract
Neurohormonal system activation is the basis of the pathogenesis of chronic heart failure. There are two main components of such activation: renin–angiotensin–aldosterone and sympathetic nervous system activation. Interruption of these processes plays a crucial role in the effective treatment of heart failure. Mineralocorticoid (aldosterone) receptor antagonists diminish the response of renin-angiotensin-aldosterone activation. Spironolactone or eplerenone (mineralocorticoid receptor antagonists) are administrated to improve symptoms, reduce the risk of heart failure hospitalization and the risk of premature death.
Article Details
How to Cite
Konopka , M., & Kuch , M. (2012). What is new in heart failure guidelines ESC 2012 – eplerenone. Medycyna Faktow (J EBM), 5(4(17), 34-37. Retrieved from https://www.journalsmededu.pl/index.php/jebm/article/view/2439
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. McMurray J.J., Clinical practice. Systolic heart failure. N. Engl. J. Med. 2010; 362: 228-238.
2. McMurray J.J., Adamopoulos S., Anker S. et al.: ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur. Heart J. [online: doi: 10.1093/eurheartj/ehs104].
3. US Food and Drug Administration.
4. Pitt B., Remme W., Zannad F. et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 2003; 348: 1309-1321.
5. Zannad F., McMurray J.J., Krum H. et al.: Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. 2011; 364: 11-21.
2. McMurray J.J., Adamopoulos S., Anker S. et al.: ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur. Heart J. [online: doi: 10.1093/eurheartj/ehs104].
3. US Food and Drug Administration.
4. Pitt B., Remme W., Zannad F. et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 2003; 348: 1309-1321.
5. Zannad F., McMurray J.J., Krum H. et al.: Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. 2011; 364: 11-21.